Radiation oncology firm Elekta has received clearance from the U.S. Food and Drug Administration (FDA) for a new radiation dose tracker for use with intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT).
iViewDose is an electronic portal imaging device (EPID) in vivo dosimetry software package. It was developed jointly by Elekta and the Netherlands Cancer Institute at Antoni van Leeuwenhoek Hospital in Amsterdam. iViewDose detects errors in radiotherapy that cannot be indentified with pretreatment checks, according to the firm.
The package has also received the European CE Mark, Elekta said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
